Combined plerixafor and granulocyte colony-stimulating factor for harvesting high-dose hematopoietic stem cells: Possible niche for plerixafor use in pediatric patients
| Autor: | Sivan Berger-Achituv, Efraim Sadot, Menachem Bitan, Rinat Eshel, Hila Rosenfeld-Keidar, Michal Manisterski, Aviva Pinhasov, Dror Levin, Rina Dvir, Shirley Friedman, Ronit Elhasid |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
0301 basic medicine Oncology Benzylamines medicine.medical_specialty Adolescent medicine.medical_treatment Hematopoietic stem cell transplantation Cyclams Transplantation Autologous 03 medical and health sciences 0302 clinical medicine Heterocyclic Compounds Internal medicine Granulocyte Colony-Stimulating Factor Outcome Assessment Health Care medicine Humans Child Adverse effect Hematopoietic Stem Cell Mobilization Transplantation Chemotherapy business.industry Plerixafor Hematopoietic Stem Cell Transplantation Chemokine CXCL12 Granulocyte colony-stimulating factor Surgery Haematopoiesis surgical procedures operative 030104 developmental biology Child Preschool 030220 oncology & carcinogenesis Pediatrics Perinatology and Child Health Blood Component Removal Female Stem cell business medicine.drug |
| Zdroj: | Pediatric Transplantation. 20:565-571 |
| ISSN: | 1397-3142 |
| DOI: | 10.1111/petr.12692 |
| Popis: | PB is a source of HSC, especially for autologous HCT in solid tumors. However, there is a risk of failing to achieve the target number of SC after mobilization with growth factors alone in patients who were heavily pretreated with chemotherapy or those in need for tandem transplants. SC were harvested from seven pediatric patients with solid tumors who were in need of autologous HCT following combination GCSF and plerixafor. Six of them received plerixafor after failing to achieve enough SC with GCSF only, while the seventh patient received the combined protocol upfront. All seven patients achieved the target number of SC according to their treatment protocol. There were no adverse events. All patients underwent autologous HCT using the harvested HSC and achieved full engraftment. A protocol for harvesting autologous HCT using GCSF and plerixafor is feasible and safe in children with solid tumors who had been heavily pretreated with chemotherapy or needed tandem transplants. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|